CStone CEO and senior management boost company shareholding
CStone Pharmaceuticals announced that its chief executive and executive director, dr. jianxin yang, along with other senior management, purchased 1,000,000 shares in the open market between October 20 and 22, 2025. Dr. Yang personally acquired 700,000 of these shares, using personal funds. This move underscores their conviction in the company's long-term investment value and growth prospects.
This recent acquisition adds to dr. yang's substantial investment in CStone since he became chief executive in August 2022, bringing his total open market purchases to 11,501,000 shares. Following these latest transactions, dr. yang's total shareholding represents approximately 4.81% of the company's total issued share capital as of the announcement date.
The board of directors views this increased shareholding by dr. yang and senior management as a clear indication of their unwavering commitment to and confidence in CStone's future business outlook. Dr. Yang and senior management have also indicated that further increases in their shareholding are possible when deemed appropriate.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CStone Pharmaceuticals publishes news
Free account required • Unsubscribe anytime